Navigation Links
Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
Date:4/14/2009

USA ovarian cancer accounts for 3 % of all cancer cases and is the fifth leading cause of cancer related deaths in the US.

About Paclical(R)

With the retinoid based unique platform XR-17, Oasmia has managed to produce a water soluble formulation of Paclitaxel (Paclical(R)), that does not require premedication and without the severe Cremophor(R) EL related side effects. The main indication is ovarian cancer. Other planned indications are malignant melanoma and lung cancer (NSCLC).

About Oasmia

Oasmia Pharmaceutical AB develops second and third generation cancer drugs based on nanotechnology for human and veterinary use. The broad portfolio is focused on oncology and contains several promising products in clinical and pre-clinical phase. Oasmia cooperates with leading universities and other biotech companies to discover and optimize substances with a favourable safety profile and better efficacy. The company was founded in 1998 and is based in Uppsala, Sweden.

    For more information, please contact:

    Maria Lunden
    Head of Public Relations
    Oasmia Pharmaceutical AB.
    E-mail: press@oasmia.com
    Phone: +46-0-18-50-54-40
    Information is also available at:
   http://www.ngm.se andhttp://www.oasmia.com

'/>"/>
SOURCE Oasmia Pharmaceutical AB
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
8. FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
9. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
10. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
11. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...inker.comannouncesthatanewmarketresearchreportisav...t-AGlobalMarketPerspective ,, http://www.rep...lobal-Market-Perspective.html ,, Risinginciden...nationsisaprincipalfactorinfluencinggrowthinthemam...eastcancerhasallowedwomentocomeforwardfortheiryear...
(Date:11/25/2009)...e/--SwissrayInternational,Inc.aleadingmanufacturer...todaythatitsoperationshavebeenacquiredbyaprivateSw...,smedicalimagingbrand.Theacquisitionincludedallass...entory.After25yearsofsuccessandgrowthSwissrayisnow...ntswithstableandsteadygrowth. ,, "Swissrayhaslo...
(Date:11/25/2009)...l/--NuVasive,Inc.(Nasdaq: NUVA ),amedicaldevicecom...ivesurgicaltreatmentsforthespine,announcedtodaytha...,at5:30p.m.ET/2:30p.m.PT.Theconferencecallwillfocu...ny,sproductsandwillincludecommentsfrommanagementfo...umbersare1-877-407-4018fordomesticcallersand1-201-...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Swissray International Announces New Ownership 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 1OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 2OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 3OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 4OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer 3B Study Paves Way for Potential Registration 5118 5LA BioMed study finds higher survival rate among intoxicated trauma patients 58613 1Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 1Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 2Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 3Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history 10205 4
...teria to Help Facilitate EHR Adoption in Small, Am..., March 3 The Certification Commission for Heal...rally recognized body for testing and certifying e...will develop dermatology-specific functionality cr... in part a response to an application from the Ame...
...IS, March 3 Novexel, a speciality pharmaceutical,...f novel antibiotics,designed to overcome the signi...unces today that its most advanced injectable anti... beta lactamase inhibitor, NXL104, with the,well e...has entered a second,Phase II clinical trial. , ...
Other Medicine Technology:Certification Commission for Healthcare Information Technology to Develop Dermatology-Specific Functionality Criteria for Electronic Health Record (EHR) Technology 2Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 2Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 3Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs) 4
(Date:11/26/2009)... No more letters from the North Po...lized text messages from Santa , ...increase operational efficiencies at the North Pol... keep children all over the globe informed of his ... Santa’s research department have identified...
(Date:11/25/2009)...DINA,Minn.,Nov.25/PRNewswire-USNewswire/--Whenmost...tachiropractorcanalsogivepatientsthehelptheyneed.T...eyourjaw(mandible)contacts/connectswithyourskull(t...dwithTMJdysfunctionarepainwithchewing,clickingorpo...MJdysfunctionincluding:headaches,fatigue,sleepdist...
(Date:11/25/2009)...ONGBEACH,Calif.,Nov.25/PRNewswire/--Thanksgivingme...iorsinthegreaterLongBeachareathankstoFaithInAction...denceatHome(IAH),adivisionofSCANHealthPlan.Formore...fvolunteerstodeliverwarmThanksgivingmealstoseniors...thLosAngelesandsurroundingcities. ,, "Ourwarmho...
(Date:11/25/2009)...rm survivors of testicular cancer who were treated... side effects, including neurological side effects... treated with chemotherapy, according to a new stu... the National Cancer Institute . , Marianne Bryd...University Hospital, in Bergen, Norway, and collea...
(Date:11/25/2009)..., already used to fight rheumatoid arthritis, coul... , WEDNESDAY, Nov. 25 (HealthDay News) -- A...a and rheumatoid arthritis now also shows some pro... 1 diabetes. , The drug, rituximab (Rituxan), h...sulin, even though the disease had destroyed some ...
Breaking Medicine News(10 mins):Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
...egory Laslo will travel to Washington, D.C., Sunda...t with congressional leaders and gain their suppor...earch toward a cure for epilepsy. , , Rundlett, 1...th support from Abbott. The program rallies young ...
... Phoenix, AZ, will travel to Washington, D.C., Su...meet with congressional leaders and gain their sup...research toward a cure for epilepsy. , , McArthur...nd funded by Abbott Laboratories. The program rall...
...use from intimate partners spent 42 percent more o...rding to a long-term study of more than 3,000 wome... The study revealed that women who suffered physic...cal and emotional pain it causes, domestic violenc...
...ces, Inc. announced today that it has provided $19...spital in Mountain View, California. The five-year...y of Siemens Medical Solutions equipment which wil...e than 40 years, El Camino Hospital has been servi...
...ty, IA will travel to Washington, D.C., Sunday, Ma...h congressional leaders and gain their support for... toward a cure for epilepsy. , , Carlson, 16, is ... by Abbott Laboratories. The program rallies young...
...Inc., the premier cancer diagnostics company and t...ay announced the appointment of Grady Barnes, Ph.D...o Fujirebio Diagnostics with 25 years of diagnosti...dian Bioscience. , , As Chief Scientific Officer,...
Other Medicine News:Health News:Maryland Youths Share Epilepsy Message on Capitol Hill 2Health News:Arizona Youth Shares Epilepsy Message on Capitol Hill 2Health News:Physical abuse raises women's health costs over 40 percent 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 3Health News:Iowa Youth Shares Epilepsy Message on Capitol Hill 2Health News:Fujirebio Diagnostics Appoints Grady Barnes as Chief Scientific Officer 2
USA Series MICRO-6L Semi-Rigid Ureteroscope
...he ACMI DUR-8 Elite's 8.7 Fr shaft reaches into th...iding complete intrarenal access, even reaching th... covering and working channel ease insertion of bo...stable shaft construction, tight-bend radius tip, ...
...he ACMI USA Series DUR-8 Durable Flexible Ureteros...e entire intrarenal collecting system with little ... secondary deflection allow complete intrarenal ac...ction facilitates access to the proximal ureter an...
S-Series Cystourethroscope Standard Obturator
Medicine Products: